AP

Ascentage Pharma

Suzhou, China

About

Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors.

Position in the VCSift Database

  • 3,884 investors in VCSift focus on the healthtech sector.
  • 118 investors are based in Suzhou, Jiangsu, China.

Data sourced from 410,343 investor profiles. Updated July 2026.

Investment Focus

Contact Information

bd••••@ascentagepharma.com
linkedin.com/in/••••••••

Unlock contact details with a VCSift subscription

Unlock Contact

Already subscribed? Log in

Find more investors like Ascentage

Search Investors